PI3K/AKT/ERK/CREB activator 1

PI3K/AKT/ERK/CREB activator 1 是一种口服有效的 PI3K/AKT/ERK/CREB 通路激活剂,可维持神经元存活与功能、促进神经元增殖、恢复损伤神经元的活力并促进突触形成,还能通过降低促炎细胞因子水平减轻神经炎症,在阿尔茨海默症模型中保留突触超微结构并恢复空间记忆,因此可用于阿尔茨海默病的相关研究。
产品编号: MS-W71667 CAS No.: 3107309-22-5 分子式: C47H73N2O13P 分子量: 905.06
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PI3K/AKT/ERK/CREB activator 1 是一种口服有效的 PI3K/AKT/ERK/CREB 通路激活剂,可维持神经元存活与功能、促进神经元增殖、恢复损伤神经元的活力并促进突触形成,还能通过降低促炎细胞因子水平减轻神经炎症,在阿尔茨海默症模型中保留突触超微结构并恢复空间记忆,因此可用于阿尔茨海默病的相关研究。

生物实验数据

生物活性 PI3K/AKT/ERK/CREB activator 1 is an orally active PI3K/AKT/ERK/CREB pathway activator that maintains neuronal survival and function, promotes neuronal proliferation, restores the viability of injured neurons, and facilitates synapse formation, and it also alleviates neuroinflammation by reducing pro-inflammatory cytokine levels, preserves synaptic ultrastructure and restores spatial memory in Alzheimer's disease models, and can therefore be used for research related to Alzheimer's disease.
体外研究
(In Vitro)

PI3K/AKT/ERK/CREB activator 1 (Compound A18) (60 μM; 48 h) 可强效促进 SH-SY5Y 细胞增殖,在 60 μM 作用 48 h 时使细胞活力提升 29.4%。
PI3K/AKT/ERK/CREB activator 1 (60 μM; 48 h) 可显著挽救 Rotenone (MS-D42728) 损伤的 SH-SY5Y 细胞,在 60 μM、作用 48 h 时可使细胞活力提升 42.5%。

Cell Proliferation Assay

Cell Line: SH-SY5Y
Concentration: 60 μM
Incubation Time: 48 h
Result: Enhanced SH-SY5Y cell viability by 29.4% compared to the control group, with a statistically significant effect.

Cell Viability Assay

Cell Line: SH-SY5Y (Rotenone-injured)
Concentration: 60 μM
Incubation Time: 48 h (added 4 h after 5 μM Rotenone exposure)
Result: Increased the viability of rotenone-injured SH-SY5Y cells by 42.5% compared to the rotenone-only control group, with a highly statistically significant effect.
体内研究
(In Vivo)

PI3K/AKT/ERK/CREB activator 1 (Compound A18) (25-100 mg/kg; 灌胃; 每日一次共 23 天) 在 Aβ1-42 诱导的阿尔茨海默病小鼠模型中展现出强效的多模态疗效。

Animal Model: C57BL/6 (male, 3-month-old, 28-32 g, SPF, wild-type, Alzheimer's disease model via unilateral intracerebroventricular injection of aggregated Aβ1-42 peptide)
Dosage: 25 mg/kg/day; 50 mg/kg/day; 100 mg/kg/day
Administration: oral gavage; daily; 23 consecutive days
Result: Significantly increased platform crossings and target quadrant occupancy at 25 mg/kg/day, with platform crossing frequency following a dose-dependent trend: 25 mg/kg > 50 mg/kg > 100 mg/kg.
Reduced escape latency and enhanced spatial orientation compared to the Aβ-only group across all treated groups.
Reversed Aβ1-42-induced neurodegeneration, with higher neuronal density in the hippocampal CA1 region compared to the Aβ-only group, and preserved intact synaptic ultrastructure with defined presynaptic membranes and ordered vesicles.
Suppressed Aβ-induced glial activation, reducing Iba-1+ microglial density and GFAP immunofluorescence intensity, and downregulated hippocampal TNF-α and IL-6 mRNA levels by 40-60%.
Increased hippocampal protein levels: CHRM5, phosphorylated PI3K, AKT, ERK, phosphorylated CREB, and synaptophysin.
Facilitated weight recovery in Aβ-injected mice, with the 25 mg/kg group showing the most rapid recovery to levels comparable to the blank control by day 21.

化学信息

分子量 905.06
分子式 C47H73N2O13P
CAS No. 3107309-22-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础